全数字化X线立体定位及活体组织检查对诊治乳腺不可触及病变的价值  

Diagnostic value of fully digital X-ray stereotactic needle localized and biopsy in non-palpable breast lesions

作　　者：赵玉年[1] 秦建伟[1] 韦达[1] 王慧华[1] 徐新宇[1] 顾慷[1] 秦锦霞[1] 

机构地区：[1]江苏省肿瘤医院放射科,南京210009

出　　处：《实用医学影像杂志》2014年第3期162-165,共4页Journal of Practical Medical Imaging

基　　金：江苏省肿瘤医院面上基金项目(ZM201110)

摘　　要：目的探讨全数字化X线立体定位及活体组织检查对临床不可触及乳腺病变(NPBL)的诊断及应用价值。方法 95例临床触诊阴性乳腺数字钼靶摄片发现微小病变。乳腺影像报告和数据系统(BI-RADS)分级4或4以上。27例行立体定位穿刺活检(SCNB);68例行立体定位下导丝引导活检(SNLB)。结果 27例SCNB,25例病理结果一致,2例病理结果低估,活检符合率92%。68例SNLB均定位成功,病变完全切除,符合率100%。结论 SCNB使乳腺良性病变切取数目降到最低,创伤小、费用低,诊断准确率高。SNLB获得的病理诊断准确、可靠。两者相比较SNLB弥补了SCNB的取材不足及假阴性,能够获得可靠的病理结果,一次同时完成诊断和治疗。Objective To discuss the diagnostic value of digital stereotactic core needle biopsy （SCNB）and stereotactic needle localized biopsy（SNLB）for non-palpable breast lesion （NPBL）. Methods Ninety-five cases having imaging abnormalities yet with non-palpable breast lesions, breast imaging reporting and date system （BI-RADS） grad-ing asⅣand above Ⅳ. Twenty-seven cases having been stereotactic core needle biopsy （SCNB）. Sixty-eight cases having been stereotactic needle localized biopsy （SNLB）. Results Twenty-seven cases having been stereotactic core needle biopsy （SCNB）. Twenty-five cases pathologic of biopsy specimen were confirmative successful （92%）. Two cases pathologic of biopsy specimen were underestimated. Sixty-eight cases had been stereotactic needle localized biopsy, 68 lesions were successful localized and completely excised with pathologic of biopsy specimen were confirma-tive successful （100%）. Conclusion The SCNB of NPBL is taken to minimize the number of breast benign lesions, small trauma and a little cost,high diagnostic accuracy. The SNLB of NPBL is an accurate and reliable method for detection of early breast lesions. By comparison SNLB make up for the lack of SCNB materials and false negative ,to obtain the reliable pathological results. And therefore, diagnostic and therapeutic one-step surgical procedures could be performed.

关 键 词：乳房X线摄影术 活组织检查 放射外科手术 

分 类 号：R737.9[医药卫生—肿瘤]